#1 Ranked Children’s Hospital by U.S. News & World Report
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
There are many ways you can help children and their families get the care they need.
Research Interests: Pathophysiology and treatment of end-stage renal disease (ESRD) in children, Clinical Trials, Novel Immunosuppression. Tolerance induction.
Summary: Dr. Harmon is internationally recognized as a leader in pediatric organ transplantation. He serves on several NIH Study Sections evaluating and promoting transplant and dialysis research and is currently a permanent member of DDK-D. He is the President of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) organization. Dr. Harmon has served as the President of the American Society of Transplantation (AST), as well as serving as its Secretary-Treasurer and the Chairman of its Public Policy and Pediatrics Committees; the Board of Directors of the International Pediatric Transplant Association (IPTA); the Transplant Advisory Group and the Policy Committee of the American Society of Nephrology; and the Public Policy and Advocacy Committee of the American Society for Pediatric Nephrology. Dr. Harmon's prominence in pediatric transplantation led to his appointment as the first Chairman of the permanent Pediatric Committee of the United Network for Organ Sharing (UNOS) and he has served three terms on its Board of Directors. He has also served as the Chairman of the Board of the New England Organ Bank. He has been a member of the DHHS Secretary's Advisory Committee on Transplantation (ACOT) and is currently the pediatric consultant to the Scientific Registry of Transplant Recipients (SRTR). Dr. Harmon's particular interest pertains to immunosuppression to optimize successes following pediatric renal transplantation. He developed the studies and protocols that were subsequently used as the basis for the development of the Cooperative Clinical Trials in Pediatric Transplantation (CCTPT), which was sponsored by a U01 mechanism through NIAID. These trials have been extremely productive and have been the basis of new techniques for provision of renal transplantation to children. One of the most innovative components of these studies are mechanistic studies that are integral to all clinical trials, including the description and analysis of intragraft gene expression, effector and regulatory T cell responses, monitoring of alloantibody production, and blood and urine monitoring by gene arrays as biomarkers of ongoing rejection or tolerance. Dr. Harmon is principal investigator on the consortium that has been awarded one of the four positions in the newly organized Clinical Trials in Organ Transplantation in Children (CTOT-C) and he was elected as Chair of the CTOT-C Steering Committee. In addition to these scientific studies, Dr. Harmon is actively involved in issues concerning organ donation and allocation on which he has published multiple articles. He served as the Chairman of the Board of Trustees of the New England Organ Bank, one of the largest organ procurement organizations in the United States, has served several terms on the Board of Directors of UNOS and recently participated in the Istanbul Summit on Organ Trafficking and Transplant Tourism. Dr. Harmon also has extensive experience in the elements of pediatric dialysis, specifically urea kinetic modeling to monitor and prescribe hemodialysis treatments for children. He designed and directed the US multicenter trial of recombinant human erythropoietin in children undergoing chronic dialysis. Dr. Harmon has been one of the editors for the last three editions of Pediatric Nephrology, the internationally-recognized principal comprehensive textbook in the field. He has also been an editor of both editions of Pediatric Solid Organ Transplantation.
Research interests: Focal and segmental glomerulosclerosis, renal replacement therapy in children.
Summary: As Clinical Director, Dr. Somers has significant interactions with pediatric renal fellows on our clinical service and has been involved in the training of many renal fellows and pediatric residents. Dr. Somers has initiated several mechanistic studies with members of our research training faculty. His active clinical research interests include the application of continuous renal replacement therapies in children with acute kidney injury as well as therapies in pediatric nephrotic syndrome. Dr. Somers is the local Principal Investigator on an NIH-sponsored multicenter trial for treatment of Focal Segmental Glomerulosclerosis in children as well as the Novel Therapies Trial in Pediatric FSGS. He is also a founding Principal Investigator of the Prospective Pediatric CRRT Registry. Dr. Somers also participates actively in Harvard Medical School courses on renal physiology and pediatric physical diagnosis.
Summary: Dr. Baum's major focus is the teaching and training of fellows in clinical nephrology. In addition, Dr. Baum has several clinical research interests pertaining to her involvement with the Myelodysplasia Program at Boston Children's Hospital. She has also initiated clinical research studies in the pediatric nephrolithiasis population in collaboration with the Urology Department.
She has an interest in how bladder abnormalities might affect renal function and she is designing a registry to follow patients with myelodysplasia and assess factors that will predict long-term renal dysfunction. Dr. Baum has participated in several projects with the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) involving the effect of native renal diseases, particularly FSGS, on renal transplant outcome. She has also initiated clinical research program in pediatric nephrolithiasis in collaboration with the Urology Department.
Summary: Dr. Rodig has developed clinical research studies involving translational mechanisms related to the outcome and treatment of pediatric patients with end-stage renal disease. She has a significant interest in transplantation and in immunosuppression. Dr. Rodig is the local Principal Investigator for an NIH-sponsored prospective multi-center study of Chronic Kidney Disease in Children. Through these activities she has significant interactions with all pediatric renal fellows while on the clinical service.
Research Interests: Urinary tract infection, vesicoureteral reflux.
Summary: Dr. Daouk directs out patient clinics in affiliated hospitals and at Boston Children's Hospital outreach centers. He is significantly involved in the teaching of renal fellows while training on the clinical service. Dr. Daouk has an interest in pediatric urinary tract infection and vesicoureteral reflux and serves as center Principal Investigator on a NIH-sponsored multicenter trial of Randomized Intervention for Children with Vesicoureteral Reflux.
We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”